Mylan's (MYL) net profit rose 11% to $180.2M as double-digit growth at the company's specialty segment and in its foreign generics business counter-balanced a 45% drop in revenue from new products following approval delays.
Gross margin increased to 44% from 43.1%.
Projects 2014 EPS of $3.25-3.60 vs consensus of $3.38 and revenue of $7.8-8.2B vs $7.75B.
Mylan expects to make another "substantial transaction" this year, although the company didn't provide details.
Shares are +3%. (PR)